RE: realistic thoughts6 Jul 2019 12:11
But looking at the other side of the argument...
1.motif main issue is to raise funds which will be known once the fda and motif reach an understanding of the trial requirement but this process takes time as we all should understand.
2.raising funds for a company for future investment blockbuster AB which can generate huge income is a very attractive proposition for many bigger fish to take seriously.
3. Motif is not selling a failing product or raising cash to prompt up a failing company.
4.No warning signs of top management resigning or leaving for a better opportunity.
5.new high profile recruitment Andrew Powell with his reputed success in M&A and surely there must be a purpose of bringing him in and why would he accepts the new position after fda turned down the nda? Surely he would not tarnish his good reputation in the knowledge that motif is going under...seems daft and nonsensical.
6.No signs of auditors,brokers leaving.
7. From the ceo latest interview, webcast...he reassured that a clear path forwards was in place and all bases are covered. Why would he say all this ...obviously not that naive to trying to deceive everyone and destroy the company he was trying to build his reputation on with others in top management. This will be considered market manipulation and abuse that could land him being investigated and in jail for up to 7 years!
8. Again in his last interview he confirmed interesting third parties in usa and outside with ongoing discussions with motif.
9.motif product has been successful in all trials undergone by motif and no death,no efficacy problem or inferiority,no liver damage detection in these trials which were done and as we all understood all were conducted in the prior knowledge of the fda discussion with motif.
10. The need for a new AB like Iclaprim is dire so why raising funds should be a problem at this stage of one more step to success.
11. Why do we think that Iclaprim might fail in another trial while it passed in every past one!?
12.for any third party this is an ideal situation for them to take advantage of motif current weakness and invest for future needed product that can generate huge income.
13.we need to remember that the fda did not reject the nda or Iclaprim but encouraged motif for another trial before approval so I read this as they wanted it to be approved but more data is required to be sure of potential liver toxicity...
14. Big ii are still holding over 21% ....
The market crushed the sp due to bod over-talked their promises and failed to deliver in TIME...and running out of finance plans as bod failed t
Market always like bod underestimate their ambitions but over delivering but not otherwise as in this case .
I look at motif from a different view point..
I also hold two other bio pharma and did very well and both are coming from the bottom sp after financial difficulties.
Just my take on motif and remain hopeful for a good news .
I do not see it going bust .
Sign In
Follow the stocks
